Dyax — Technical Presentation (March 2015)
36 slides from Dyax's technical presentation, Mar 31, 2015
Slide 1: DX-2930 Phase 1b Data Review
DX - 2930 Phase 1b Data Review MARCH 31, 2015
Slide 2: Forward Looking Statements
This presentation contains forward - looking statements, including statements regarding the prospects for therapeutic benefits and treatment advantages of an investigational product, DX - 2930, being developed by Dyax for hereditary angioedema (HAE). Statements that are not historical facts are base
Slide 3: DX-2930 Phase 1b Data Review
ae DX-2930 Phase 1b Dyax Data Review
Slide 4: Phase 1b Data Review Presenters
DX - 2930 phase 1b data review Presenters Burt Adelman, Executive Vice President of R&D and Chief Medical Officer Ryan Iarrobino, Senior Director Clinical Development Dan Sexton, Distinguished Scientist Yung Chyung, Vice President Medical Research 4
Slide 5: Phase 1b study
5 DX - 2930 phase 1b study Key analyses: Safety & tolerability Pharmacokinetic profile Pharmacodynamic bioactivity Efficacy in preventing HAE attacks M ulti - center , randomized, placebo - controlled, multiple ascending dose trial in subjects with HAE
Slide 6: Phase 1b study design
6 DX - 2930 phase 1b study design 3 dosing cohorts originally planned: 30 mg, 100 mg, 300 mg Subjects randomized to active drug vs placebo in 2:1 ratio (each subject receives 2 doses separated by 14 days ) Follow - up visits occur through 15 weeks following second dose Protocol allows for ex
Slide 7: Expansion and data analysis
7 Expansion and data analysis 16 additional subjects randomized to 400 mg DX - 2930 or placebo (overall total of 37 treated subjects) Data analysis was conducted after all subjects in the 400 mg dose group completed Day 50 follow - up visit Analyses include safety, pharmacokinetics, pharmacody
Slide 8: Subject disposition and demographics
8 Subject disposition and demographics Disposition • One subject in the 400 mg dose group received only one dose and was replaced. • No subjects discontinued due to adverse events . DX - 2930 and Placebo were balanced in terms of age, race , ethnicity, and BMI. • Slightly more females in DX - 29
Slide 9: Phase 1b Safety
Phase 1b Safety
Slide 10: Summary of adverse events
10 Summary of adverse events DX - 2930 30 mg (N = 4) DX - 2930 100 mg (N = 4) DX - 2930 300 mg (N = 5) DX - 2930 400 mg (N = 11) DX - 2930 total (N = 24) Placebo (N = 13) Adverse events (AEs)* 1 3 2 8 14 (58%) 10 (77%) Deaths or discontinuations due to AEs 0 0 0 0 0 0 Serious adverse events 0 0 0 0
Slide 11: Adverse events
11 Adverse events Most common AEs were HAE attacks, injection site pain, and headache; r ates not appreciably higher in DX - 2930 2 subjects with 3 related severe TEAEs • One DX - 2930 subject (30 mg) with injection site pain lasting 1 minute • One DX - 2930 subject (400 mg) with worsening heada
Slide 12: Summary of safety assessments
12 Summary of safety assessments No safety signals identified for ● Vital signs ● P hysical examinations ● Clinical laboratory tests ● Electrocardiogram (ECG)
Slide 13: Summary of safety
13 Summary of safety R esults suggest DX - 2930 was well tolerated in this study N o evidence of dose - limiting toxicity at doses up to 400 mg
Slide 14: Phase 1b Pharmacokinetics and Pharmacodynamics
Phase 1b Pharmacokinetics and Pharmacodynamics
Slide 15: Pharmacokinetics: mean concentration following SC administration
15 Mean DX - 2930 concentration following SC administration to HAE subjects Pharmacokinetics Note: 400 mg PK analysis excludes one patient who received only 1 dose of DX - 2930. C max ( ng /ml) T max (day) t ½ (day) 30 mg 4063.2 20 14.3 100 mg 7728.1 21 14.7 300 mg 31275.7 19.6 13.8 400 mg pending p
Slide 16: Levels of HMWK cleavage in citrated plasma
16 Levels of HMWK cleavage in citrated plasma 300 and 400 mg DX - 2930 reduce biomarker activity in HAE subjects to levels seen in healthy subjects One - Way Analysis of Variance. %2 - chain in each dose group at day 8 and 22 compared to all subject predose %2 - chain. error bars = SEM. HV = healthy
Slide 17: Phase 1b Efficacy
Phase 1b Efficacy
Slide 18: Primary efficacy assessment period
18 Primary efficacy assessment period 300 mg DX - 2930 400 mg DX - 2930 0 5,000 10,000 15,000 20,000 25,000 30,000 35,000 40,000 45,000 -50 0 50 100 DX - 2930 (ng/mL) Study Day 0 5,000 10,000 15,000 20,000 25,000 30,000 35,000 40,000 45,000 -50 0 50 100 DX - 2930 (ng/mL) Study Day Notable drug expos
Slide 19: Prospective primary efficacy analysis
19 Prospective primary efficacy analysis Included subjects with a minimum baseline history of at least 2 attacks in the 3 months (0.15 attacks/week) prior to study ● 11 of 13 placebo subjects ● 15 of 16 subjects treated with 300 or 400 mg DX - 2930 Baseline HAE attack rates (attacks/week) ● Plac
Slide 20: Primary efficacy analysis (Day 8 to 50)
20 Primary efficacy analysis (Day 8 to 50) DX - 2930 300 mg (N = 4) DX - 2930 400 mg (N = 11) DX - 2930 Combined 300 and 400 mg (N = 15) % Reduction vs placebo 100 88 91 P - value vs placebo * <0.0001 0.005 0.0012 Note: Only subjects who have a baseline attack rate of at least 2 attacks in the last
Slide 21: Observed attack rates
21 Observed attack rates (over placebo) Note: Baseline is defined as historical HAE attacks over last 3 months prior to dosing. Only includes patients with a baseline rate of ≥ 2 attacks in the last 3 months. Day 8 to 50 a ttack rates are adjusted for baseline rates. Percent reduction in HAE attack
Slide 22: Proportion of subjects who were attack-free
22 Proportion of subjects who were attack - free (Day 8 to 50) Note: Only subjects who have a baseline attack rate of at least 2 attacks in the last 3 months are included . Fisher exact test for each treatment arm vs. placebo. DX - 2930 300 mg (N = 4) DX - 2930 400 mg (N = 11) DX - 2930 Combined 300
Slide 23: Characteristics of HAE attacks (Day 8 to 50)
23 Characteristics of HAE attacks (Day 8 to 50) DX - 2930 300 mg (N = 4) DX - 2930 400 mg (N = 11) Placebo (N = 11) Attacks 0 3 24 Primary Attack Location Peripheral 0 3 10 Abdominal 0 0 13 Laryngeal 0 0 1 Attack Severity Mild 0 1 8 Moderate 0 1 6 Severe 0 1 10 Acute attacks requiring treatment 0 2
Slide 24: Modified intent-to-treat (MITT) analysis
24 Modified intent - to - treat ( M ITT) analysis Goal: Evaluate clinical effects in the context of HAE patients receiving the dose regimen as specified Post - hoc analysis Same as ITT population except 2 subjects excluded ● 1 subject received only 1 administration of DX - 2930 (subject discon
Slide 25: Primary efficacy analysis (modified intent-to-treat analysis)
25 Primary efficacy analysis (Day 8 to 50) (modified intent - to - treat analysis) Note: Only subjects who have a baseline attack rate of at least 2 attacks in the last 3 months are included . M ITT population excludes 2 subjects, one subject without type I or II HAE and one subject who received onl
Slide 26: Attack incidence plotted against mean PK curves
26 Attack incidence plotted against mean PK curves Drug Concentration Time Attacks o bserved Few or n o attacks Attacks r e - emerge Hypothesis: Higher DX - 2930 drug levels should be associated with few or no attacks Note: Hypothetical data for illustrative purposes.
Slide 27: Incidence of HAE attacks in placebo-treated subjects
27 Incidence of HAE attacks in placebo - treated subjects -50 0 50 100 Attack Day 8 to 50 n = 13
Slide 28: Mean PK plots and HAE attack incidence: 30 and 100 mg
28 Mean PK plots and HAE attack incidence following 30 and 100 mg DX - 2930 0 5,000 10,000 15,000 20,000 25,000 30,000 35,000 40,000 45,000 -50 0 50 100 DX - 2930 (ng/mL) Study Day 30 mg (n = 4) Attack 0 5,000 10,000 15,000 20,000 25,000 30,000 35,000 40,000 45,000 -50 0 50 100 DX - 2930 (ng/mL) Stu
Slide 29: Mean PK plots and HAE attack incidence: 300 mg
29 Mean PK plots and HAE attack incidence following 300 mg DX - 2930 0 5,000 10,000 15,000 20,000 25,000 30,000 35,000 40,000 45,000 -50 0 50 100 DX - 2930 (ng/mL) Study Day 300 mg (n = 5) Attack Day 8 to 50
Slide 30: Mean PK plots and HAE attack incidence: 400 mg
30 Mean PK plots and HAE attack incidence following 400 mg DX - 2930 Note: Excluding patient who received only one dose (this was necessary to derive the mean pharmacokinetic curve). 0 5,000 10,000 15,000 20,000 25,000 30,000 35,000 40,000 45,000 -50 0 50 100 DX - 2930 (ng/mL) Study Day 400 mg (n =
Slide 31: Concentration and HAE attacks in patients with high historical attack rate
31 DX - 2930 concentration and HAE attacks in patients with historical attack rate ≥ 9 attacks in past 3 months -45 5 55 105 DX - 2930 (ng/mL) Study Day Placebo Historically: 35 attacks in last 3 months 0 10,000 20,000 30,000 40,000 50,000 -45 5 55 105 DX - 2930 (ng/mL) Study Day 300 mg Historically
Slide 32: Concentration and HAE attacks in patients with high historical attack rate
32 DX - 2930 concentration and HAE attacks in patients with historical attack rate ≥ 9 attacks in past 3 months 0 10,000 20,000 30,000 40,000 50,000 -45 5 55 105 DX - 2930 (ng/mL) Study Day 400 mg Historically: 9 attacks in last 3 months 0 10,000 20,000 30,000 40,000 50,000 -45 5 55 105 DX - 2930 (n
Slide 33: Summary of Phase 1b
33 Summary of phase 1b No apparent safety signals have emerged to date for DX - 2930 PK profile is consistent with that of a monoclonal antibody, supporting dosing once every 2 weeks (or less frequently) Kininogen biomarker assays demonstrate DX - 2930 normalizes instability of HAE plasma A
Slide 34: Regulatory Update
LD Dya Regulatory Update
Slide 35: Regulatory update
Regulatory update • US Status • Orphan Drug designation • Fast Track designation • US Next Steps • Phase 1b data to inform the design and discussion of the Phase 3 pivotal trial design with the FDA • EU Next Steps • Meet with EU regulators for scientific advice regarding evidence required for approv
Slide 36: Phase 1b Data Review: contact information
DX - 2930 Phase 1b Data Review MARCH 31, 2015 For additional information, please contact: Jennifer Robinson 617 - 250 - 5741 [email protected]